Vertex Pharmaceuticals Incorporated
VRTX
$489.10
$3.210.66%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -114.80% | -113.83% | -114.56% | 23.31% | 8.96% |
| Total Depreciation and Amortization | 7.37% | 29.37% | 26.72% | 21.83% | 14.30% |
| Total Amortization of Deferred Charges | 113.56% | -- | -- | -- | -- |
| Total Other Non-Cash Items | 16,595.24% | -21.39% | -42.81% | -97.40% | -99.34% |
| Change in Net Operating Assets | -93.75% | -264.52% | -303.66% | -153.72% | -177.96% |
| Cash from Operations | -113.93% | -119.23% | -123.20% | -3.18% | -14.35% |
| Capital Expenditure | -48.55% | -49.63% | -24.59% | -23.74% | 2.10% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -18.05% | -87.60% | -81.02% | -98.07% | -1,738.61% |
| Cash from Investing | -20.00% | -84.39% | -53.63% | -63.74% | -878.42% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 25.17% | -2.31% | 38.40% | 42.91% | 47.49% |
| Issuance of Common Stock | -14.86% | -9.37% | -16.96% | -17.69% | -27.75% |
| Repurchase of Common Stock | -142.02% | -160.31% | -185.74% | -103.16% | -280.06% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | 244.44% | 322.22% | 700.00% | 2,200.00% | -- |
| Cash from Financing | -165.90% | -204.18% | -236.55% | -134.08% | -730.43% |
| Foreign Exchange rate Adjustments | -258.36% | -20.35% | -153.66% | 93.81% | 192.12% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -4,051.83% | -402.56% | -483.80% | -107.46% | -103.76% |